HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME Oct. 05, 2023 8:05 AM ET Harmony Biosciences Holdings, Inc. (HRMY) ...

Healthcare has too often been reactive. But a more forward-thinking approach, using tools and technologies for RPM, can help reduce readmissions, improve patient outcomes and enable success with value ...

Experts discuss the unmet clinical and economic needs in arrhythmia evaluation—particularly in patients with comorbidities—highlighting how early detection and predictive solutions can improve ...

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

Poster: Secondary Outcomes from a Phase 2, Double-Blind, Placebo-Controlled Signal-Detection, Proof-of-Concept Study of Pitolisant in Prader-Willi Syndrome The Phase 2 clinical trial was a ...